Evidence map›Paper›PMID 38133322›Full record

ArticlePathogens (Basel, Switzerland)2023

Extrapulmonary and Drug-Resistant Childhood Tuberculosis: Unveiling the Disease to Adopt the Optimal Treatment Strategy.

Domenico Pace, Francesca Corvaglia, Catiuscia Lisi, Luisa Galli, Elena Chiappini

Open access · goldAbstract read
In one paragraph

Article in Pathogens (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Domenico PaceInfectious Disease Unit, Department of Health Sciences, Meyer Children's Hospital IRCCS, University of Florence, 50121 Florence, Italy.
Francesca CorvagliaInfectious Disease Unit, Department of Health Sciences, Meyer Children's Hospital IRCCS, University of Florence, 50121 Florence, Italy.
Catiuscia LisiInfectious Disease Unit, Department of Health Sciences, Meyer Children's Hospital IRCCS, University of Florence, 50121 Florence, Italy.
Luisa GalliInfectious Disease Unit, Department of Health Sciences, Meyer Children's Hospital IRCCS, University of Florence, 50121 Florence, Italy.ORCID 0000-0002-7912-3366
Elena ChiappiniInfectious Disease Unit, Department of Health Sciences, Meyer Children's Hospital IRCCS, University of Florence, 50121 Florence, Italy.
Meyer Children's Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Paediatric tuberculosis (TB) is a substantial threat among infectious diseases, particularly considering the high risk of extrapulmonary tuberculosis (EPTB), severe forms of the disease, and the spreading of drug-resistant strains. Describing the characteristics of children with EPTB and those with drug-resistant tuberculosis (DR-TB) and analysing the role of second-line drugs could facilitate the management of these cases. This retrospective study was conducted on 271 children diagnosed with active TB disease (44 EPTB cases, 9 DR-TB cases), originating from diverse geographic areas, who were referred to the infectious disease unit at Meyer Children's Hospital, Florence, Italy, from 2006 to 2022. In most patients, the management of therapies was complicated by the impossibility to obtain drug susceptibility testing (DST) results, which improved over the years: 17/154 (11.04%) children had DST results between 2006 and 2013, and 50/117 (42.73%,

Indexed as

childrendrug resistanceextrapulmonary tuberculosissecond-line drugstherapytuberculosis

Identifiers

PMID38133322
PMCPMC10745899
OpenAlexW4389623772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.